Early glottic cancer (Tis, T1a, T1b, T2) is one of the most curable malignancies in the head and neck. Not only does the symptom of hoarseness allow an early diagnosis, but also, as a result of the glottis’ peculiar lymphatic drainage less than 1% of patients develop cervical metastasis.
Laser surgery, being an alternative treatment for early glottic cancer, affords optimal oncologic radicality. Overall survival rate reached 90%.
This can only mean that adopting laser treatment with using professional and effective laser machines will most probably guarantee full and quick recovery.
The FDA Portable 980nm Surgery Laser System SIFLASER-1.2B presents itself as one of the most recommended devices among surgeons viewing its high-efficacy in treating such type of cancer.
This device’s blue laser light interacts better with the tissue components haemoglobin or melanin. At 980 nm, the machine performs better and gentler cutting, even at lower power.
As such, its improved cutting performance makes it ideally suited to all surgical applications, particularly for early glottic cancer.
What also makes the SIFLASER-1.2B highly recommended by surgical oncologists is that it displays an accurate alignment and exact sighting during the treatment. All thanks to its green aiming beam.
To further improve the treatment, the device is supported with a fibre guide laser. So, it is compatible with various endoscopic uses. Also, these special fibres are sterilisable which, in turn, prevents any possible cross-infection while guaranteeing a clean and bloodless operative area.
With 980 nm wavelength and 15W as maximum power, the device is thought to perfectly suit early-Glottic cancer highly-sensitive surgeries.
That is highly attributed to the fact that The SIFLASER-1.2B uses infrared wavelengths and ultra-blue light to ensure high-level performance.
That is also estimated to reduce the thermal damage and to its peculiar interaction with haemoglobin.
Due to all these features, the SIFLASER-1.2B guarantees increased cutting effectiveness, much higher than the one obtained with infrared lasers.
Since their invention, laser use and applications have expanded rapidly as it proved to be a successful addition to cancer surgery.
In this article, we discuss the benefits of laser therapy and precisely the efficacy of SIFLASER-1.2B as a surgical laser device in treating Early Glottic Cancer.
Disclaimer: Although the information we provide is used by different doctors and medical staff to perform their procedures and clinical applications, the information contained in this article is for consideration only. SIFSOF is not responsible neither for the misuse of the device nor for the wrong or random generalizability of the device in all clinical applications or procedures mentioned in our articles. Users must have the proper training and skills to perform the procedure with each Laser System.
The products mentioned in this article are only for sale to medical staff (doctors, nurses, certified practitioners, etc.) or to private users assisted by or under the supervision of a medical professional.